A prognostic 4-gene expression signature for patients with HER2-negative breast cancer receiving taxane and anthracycline-based chemotherapy

Breast cancer is a heterogeneous group of diseases with diverse clinicopathological and molecular features. At present, chemo-resistance still poses a major obstacle to successful treatment of HER-2 negative breast cancer. Reliable biomarkers are urgently needed to accurately predict the therapeutic...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Pu, Wang, Zhen, Hu, Guoming, Huang, Qi, Han, Mengjiao, Huang, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732731/
https://www.ncbi.nlm.nih.gov/pubmed/29262565
http://dx.doi.org/10.18632/oncotarget.21872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732731/
https://www.ncbi.nlm.nih.gov/pubmed/29262565
http://dx.doi.org/10.18632/oncotarget.21872

Ejemplares similares